Figure 7

Effects of Saxagliptin on migration and tubulisation of PACs. A) Representative microphotographs of tube formation in 2D Matrigel by HUVECs co-cultured with PACs from type 2 diabetic patients and healthy controls exposed to Saxagliptin with or without SDF-1α supplementation. B-C) Quantification of total tube length formation by HUVECs alone and HUVECs co-incubated with PACs either untreated (Ctrl) or treated with Saxagliptin and/or SDF-1α. Panel B shows data obtained with PACs from type 2 diabetic patients, while panel C shows data obtained with healthy PACs. *p < 0.05 versus HUVECs alone, set at 1.0. D) Quantification of total tube length formation by HUVECs alone and HUVECs co-incubated with CD14⁺ or CD14^- PACs from healthy controls. *p < 0.05 in CD14⁺ vs CD14^- cells; ^†p < 0.05 versus the control condition. E) Red-labelled PACs co-cultured with HUVECs in the tube forming assay were imaged under an inverted fluorescence micriscioe to detect their spatial localization and quantify tubes with integrated CD14⁺ and CD14^- PACs.